Division of Interventional Science University College of London

Slides:



Advertisements
Similar presentations
Implementing NICE guidance
Advertisements

Prostate Cancer What a GP Needs to Know
The Thyroid Incidentaloma
Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.
PROSTATE CANCER Dr Samad Zare Assistant Proffesor of Urology Shaheed Sadoughi University of Medical Sciences.
Uro-symphyseal fistulation after prostatic irradiation – an unrecognised but important complication Introduction Chronic pain following external beam radiotherapy.
Ihor S. Sawczuk, M.D. PROFESSOR & CHAIRMAN UROLOGY TOURO UNIVERSITY COLLEGE OF MEDICINE ADJUNCT PROFESSOR OF UROLOGY COLLEGE OF PHYSICIANS & SURGEONS.
HIFU Douglas Chinn MD Chinn & Chinn Urology Arcadia, CA.
Integrated PET/CT in Differentiated Thyroid Cancer: Diagnostic Accuracy and Impact on Patient Management J Nucl Med 2006; 47:616–624 報告者 : 蘇惠怡.
Prostate Cancer James B. Benton,M.D.. Prostate Cancer Significant of the clinical problem Early detection/screening Prevention/Management.
Prof Stephen Langley Professor of Urology St Luke’s Cancer Centre, Guildford, UK PGMS, University of Surrey Focal Brachytherapy UK experience.
Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012.
Prostate VTP: Clinical Trial Update
Some Current Issues in the Management of Prostate Cancer Suman Chatterjee MD.
POTENTIAL FOR FAILURE OF FOCAL PROSTATE HEMI-ABLATION STRATEGIES PG O’Malley 1, B Al Hussein Al Awamlh 1, AM Sarkisian 1, DP Nguyen 1, S Jin 1, R Lee 1,
Public health research in Europe Mark McCarthy (University College London) Levels of health sciences molecules cells organs people populations Laboratory.
MR-Guided Ablation of Prostate Cancer Recurrences: Laser and Cryoablation. David A. Woodrum, Lance A. Mynderse, Akira Kawashima, Krysztof R. Gorny, Thomas.
“Prostate Cartography”: Targeted &systematic perineal stereotactic prostate biopsy using the BiopSee®platform in locating and re-locating prostate cancer.
Prostate Cancer Screening Risk Management Ben Inch.
Results Conclusions Objective & Hypothesis Background Acknowledgements: Methodology Data Analysis from Clinical Research Trials Western Kentucky University.
بسم الله الرحمن الرحیم.
David Spellberg, MD Naples Urological Associates High Intensity Focused Ultrasound Sonablate ® HIFU A Minimally Invasive Way to Treat Prostate Cancer.
David Spellberg M.D., FACS
Updated 12/7/07 High Intensity Focused Ultrasound Sonablate ® HIFU A Non Invasive Way to Treat Prostate Cancer.
HIFU AND CRYOSURGERY David Spellberg M.D., FACS.
Prostate cancer update Suresh GANTA Consultant urological surgeon Manor Hospital.
M Emberton Professor of Interventional Oncology Division of Surgical and Interventional Sciences, University College London Screening, diagnosis and management.
David Spellberg, M.D., FACS Naples Urology Associates, P.A.
High Intensity Focused Ultrasound Sonablate® HIFU
Manit Arya Consultant Urological Surgeon UCLH and PAH Transforming the Pathway in Prostate Cancer.
Focal Magnetic Resonance Guided Intensity Focused Ultrasound Treatment of Low Risk Prostate Cancer: A Phase I Trial. Alexandr Nosov, Sergey Kanaev, Georg.
MR-guided focal laser therapy
Alternative Treatments for Localized Prostate Cancer
Benjamin Kearns, The University of Sheffield
Indications for Breast MR Imaging
74-year-old man with stage T2a Gleason score prostate cancer (prostate specific antigen = ng/mL) in right transition zone (TZ) with history.
The HEMO Study Hemodialysis (HEMO) Study Reference
Michael Lazar MD, HPS Medical Director
Contemporary Clinical Trials
How I talk to my patients about HIFU
Safety and Potential Effect of a Single Intracavernous Injection of Autologous Adipose- Derived Regenerative Cells in Patients with Erectile Dysfunction.
Volume 66, Issue 1, Pages (July 2014)
Volume 191, Issue 6, Pages (June 2014)
Volume 74, Issue 4, Pages (October 2018)
Volume 13, Issue 6, Pages (June 2012)
Prostate Cancer: Highlights from 2006
Apollo Gleneagles Hospitals,
Volume 67, Issue 3, Pages (March 2015)
Volume 65, Issue 5, Pages (May 2014)
Volume 199, Issue 1, Pages (January 2018)
The Value of Proton Magnetic Resonance Spectroscopy in High-Intensity Focused Ultrasound Treatment of Experimental Liver Cancer  Zhuo-yue Tang, Jian-nong.
Volume 72, Issue 3, Pages (September 2017)
Volume 70, Issue 4, Pages (October 2016)
Localised and Locally Advanced Prostate Cancer: Who to Treat and How?
Volume 59, Issue 6, Pages (June 2011)
Ultrasound-guided high-intensity focused ultrasound ablation for adenomyosis: the clinical experience of a single center  Min Zhou, M.D., Ph.D., Jin-Yun.
Volume 68, Issue 6, Pages (December 2015)
P8-2 Rezum water vapour thermal therapy for benign prostatic hyperplasia: early results from the United Kingdom Max Johnston1, Tina Gehring1, James Montgomery1,
Volume 13, Issue 6, Pages (June 2012)
What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006  Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,
Volume 73, Issue 1, Pages (January 2018)
Volume 65, Issue 3, Pages (March 2014)
Prostate Cancer Update
Volume 66, Issue 1, Pages (July 2014)
Epidemiological Designs
Image-guided Irreversible Electroporation of Localized Prostate Cancer: Functional and Oncologic Outcomes Following irreversible electroporation (IRE)
My PAH Patient.
Salvage Local Treatments After Focal Therapy for Prostate Cancer
Rita Faria, MSc Centre for Health Economics University of York, UK
Single-site disease progression after 9 months of response to therapy in the right hemipelvis visualized by diffusion-weighted whole-body MRI. Top, fusion.
Presentation transcript:

Division of Interventional Science University College of London Dr Alberto Gritti Director: Mark Emberton 1

“Radical prostatectomy did not significantly reduce all cause or prostate cancer specific mortality as compared with observation”

TISSUE-PRESERVING STRATEGIES “If the opportunity to benefit is small so too must be the harms that come with the treatment” (M. Emberton) TISSUE-PRESERVING STRATEGIES

Focal Therapy as the Potential Solution Scepticism – Multifocality 80% Focal therapy may decrease the number of side effects while maintaining the benefit of treatment Novel imaging and precision biopsy can identify those lesions that are likely to progress Selective therapy to Clinically Significant lesions alone Scepticism – Multifocality 80% 7

Does an Index Lesion Exist? A Biological Approach These Lesions do not meet the criteria for Cancer Might be classified as non malignant

Which Ablative Strategy in Localised Prostate Cancer is best for Erectile Function preservation? Gritti A*, Legramanti S* ., Valerio M, Mccartan N, Dickinson L, Ahmed HU, Emberton M HYPOTHESIS Erectile Function preservation is related to the extent of prostatic tissue ablation using High-Intensity Focused Ultrasound (HIFU) in Prostate Cancer METHODS Registry-based analysis of Erectile Function before and after HIFU 169 pz Outcome measure= Δ IIEF-15 and % Penetrative Intercourse Whole-gland HIFU Hemi-ablation HIFU Focal HIFU

Multiparametric MRI Template Biopsy

THE UCL FOCAL PROGRAMME T1-weighted with gadolinium enhancement

THE UCL FOCAL PROGRAMME T1-weighted gadolinium enhancement at 1 week post Left Hemi-HIFU

RESULTS p=0.004 p=0.153

Residual Disease (any) 4-50% Significant Residual Disease 0-17% Results Value Follow-up 0-11 years Residual Disease (any) 4-50% Significant Residual Disease 0-17% Urinary Outcome (Pad-free continence) 95-100% Erectile Outcome (Penetrative Intercourse) 54-100% Recto-Urethral Fistula 0-1%

CONCLUSIONS The type of Ablative Strategy seems to have an impact on Erectile Function Comparative trials in an homogeneous population are needed to confirm these findings